Financial Results for Fiscal 2022

from the beginning

Management Policy for Fiscal 2023

Disclaimer

• 01. Performance Highlights

“Transform Olympus” - Transformation Plan to Become a Truly Global Company

Our strategic aspiration and performance metrics

Our corporate strategy

We have accelerated transformation to a global medtech company

Since announcement of Transform Olympus, we have achieved strong growth despite pandemic headwinds

Our Journey to a global medtech company

• 02. Management Policy for Fiscal 2023

FY2023 Key Initiatives

Toward a milestone of the corporate strategy

Shift towards sustainable growth

Consolidated Financial Results for Fiscal 2022 and Full-Year Forecasts for Fiscal 2023

Highlights

• 01. Consolidated Financial Results and Business Review for Fiscal 2022 (FY Ended March 31, 2022)

Fiscal 2022 (1) Consolidated Financial Results

Fiscal 2022 (2) Endoscopic Solutions Division (ESD)

Fiscal 2022 (3) Therapeutic Solutions Division (TSD)

Fiscal 2022 (4) Scientific Solutions Division (SSD)

Statement of Financial Position

Consolidated Cash Flows

• 02. Forecasts for Fiscal 2023

Fiscal 2023 Consolidated Forecasts

Fiscal 2023 Forecasts by Business Segment

• 03. ESD/TSD Key Priorities,Key Product Catalysts and Chinese Market

Key Product Catalysts: Endoscopic Solutions Division

Key Product Catalysts: Therapeutic Solutions Division

Worldwide Growth in Medical in Fiscal 2022

Growth Potential in China Remains Unchanged

@

Appendix

Fiscal 2022 Factors that Affected Consolidated Operating Profit

4Q of Fiscal 2022 Factors that Affected Consolidated Operating Profit

Fiscal 2022 Results vs. February Forecasts

Fiscal 2022 Results by Segment

Fiscal 2022 Growth Rate by Sub-segment

Expenditures, etc.

Financial guidance and supporting financial indicators

Q&A

• Q&A 1

• Q&A 2

@P13

• Q&A 3

@P27

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8